Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled phase 3 study of Upacicalcet with 27-week individualized dose titration periods in patients with SHPT due to end-stage kidney disease (ESKD) on maintenance HD

Next Previous
Search
Trial Profile

A randomized, double-blind, placebo-controlled phase 3 study of Upacicalcet with 27-week individualized dose titration periods in patients with SHPT due to end-stage kidney disease (ESKD) on maintenance HD

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upacicalcet (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Sponsors Pathalys Pharma

    • Most Recent Events

    • 17 Jan 2023 According to Pathalys Pharma media release, the company has raised 150 million dollars in secured financing and equity led by Abingworth, also strategic collaboration is formed with Launch Therapeutics to advance upacicalcet through this study.
    • 07 Apr 2022 According to a Pathalys Pharma media release, the company plans to initiate two identical phase 3 trial in 2022. The trials design presented at the National Kidney Foundation's Annual Spring Clinical Meeting (SCM22).
    • 07 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top